Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital.
| dc.contributor.author | Lens García, Sabela | |
| dc.contributor.author | Londoño, María Carlota | |
| dc.contributor.author | Forns, Xavier | |
| dc.contributor.author | Pocurull Aparicio, Anna | |
| dc.contributor.author | Moreta, Maria José | |
| dc.contributor.author | Heitman, David | |
| dc.contributor.author | Olivas, Ignasi | |
| dc.contributor.author | Collazos Clemente, Cristina | |
| dc.contributor.author | Canga, Elia | |
| dc.contributor.author | Sáez Peñataro, Joaquín | |
| dc.contributor.author | Andrade, Raúl J. | |
| dc.contributor.author | Lucena, M. Isabel | |
| dc.contributor.author | Mariño Méndez, Zoe | |
| dc.contributor.author | Diaz Lorca, Maria Alba | |
| dc.date.accessioned | 2026-02-27T15:33:48Z | |
| dc.date.available | 2026-02-27T15:33:48Z | |
| dc.date.issued | 2024-02 | |
| dc.date.updated | 2026-02-27T15:33:48Z | |
| dc.description.abstract | Drug-induced liver injury (DILI) is a challenging liver disorder for hepatologists. We aimed to assess the pattern and causes of DILI in a tertiary hospital. We registered prospectively all patients referred with suspicion of DILI from 2018 to 2023. A total of 106 patients fulfilled the diagnostic criteria (30 caused by paracetamol were excluded; total number 76). The pattern of liver injury was hepatocellular in 55 (72%). Drugs causing DILI were antineoplastic (26%), antibiotics (24%), analgesics (12%), and recreational drugs (9%). Regarding clinical outcomes, 39 (51%) required hospitalization and 7 (9%) underwent a liver transplantation or died from acute liver injury. We identified 126 additional patients with DILI due to immune check-point inhibitors who were not referred to a liver disease specialist. Antineoplastic drugs have become the first cause of DILI in hospitals. A multidisciplinary approach and specific educational tools to increase DILI awareness are needed among different specialists. | |
| dc.format.extent | 15 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 750004 | |
| dc.identifier.idimarina | 9380430 | |
| dc.identifier.issn | 1478-3223 | |
| dc.identifier.pmid | 38131512 | |
| dc.identifier.uri | https://hdl.handle.net/2445/227686 | |
| dc.language.iso | eng | |
| dc.publisher | John Wiley & Sons | |
| dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1111/liv.15821 | |
| dc.relation.ispartof | Liver International, 2024, vol. 44, num.2, p. 286-292 | |
| dc.relation.uri | https://doi.org/10.1111/liv.15821 | |
| dc.rights | (c) John Wiley & Sons, 2023 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.subject.classification | Toxicitat dels medicaments | |
| dc.subject.classification | Malalties del fetge | |
| dc.subject.classification | Medicaments antineoplàstics | |
| dc.subject.other | Drug toxicity | |
| dc.subject.other | Liver diseases | |
| dc.subject.other | Antineoplastic agents | |
| dc.title | Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital. | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/acceptedVersion |
Fitxers
Paquet original
1 - 1 de 1